基于结构发现了一系列共价,口服生物可用和选择性BFL1抑制剂
Adeline Palisse1, Tony Cheung2, Aileen Blokhuis1
1Medicinal Chemistry, Oncology, R&D, Acerta Pharma B.V., A member of the AstraZeneca Group, Oss 5349 AB, The Netherlands.
Journal of medicinal chemistry
|December 6, 2024
概括
研究人员开发了新的BFL1抑制剂,包括化合物20,用于对抗血液性恶性瘤. 这些抑制剂通过稳定BFL1蛋白并诱导癌细胞死亡,显示出有前途.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- BFL1,一种抗瘤的BCL2家族成员,在血液性恶性瘤中过度表达.
- 与其他BCL2家族成员相比,BFL1仍未得到充分研究.
研究的目的:
- 开发新的BFL1抑制剂,用于潜在的癌症治疗.
- 优化现有的化合物,以提高BFL1抑制和选择性.
主要方法:
- 基于结构的药物设计和优化.
- 协定片段库选和击中进化.
- 在体外酶分析和细胞活性评估.
- 在相关癌症模型中的体内研究.
主要成果:
- 优化化合物6成为选择性BFL1抑制剂,以化合物20为例.
- 化合物20表现出较低的纳米分子细胞活性,特别是AZD5991.1.
- 化合物20在SUDHL1和OCILY10细胞系中诱导细胞死亡.
- 在体内研究显示了剂量依赖的BFL1稳定和分裂的caspase3激活.
- 化合物20在酶循环研究中将BFL1蛋白的半衰期延长到10.8小时.
结论:
- 开发出具有治疗潜力的强效和选择性BFL1抑制剂.
- 化合物20在血液性恶性瘤的临床前模型中显示出有效性.
- 稳定BFL1是一种诱导癌细胞死亡的可行策略.
更多相关视频
06:26Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
4.7K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Drug-Receptor Bonds
2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.7K
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Ligand Binding Sites
12.7K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.7K
Noncovalent Attractions in Biomolecules
48.8K
Noncovalent attractions are associations within and between molecules that influence the shape and structural stability of complexes. These interactions differ from covalent bonding in that they do not involve sharing of electrons.
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
48.8K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
